Research Papers:

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

Finn Edler von Eyben _, Aviral Singh, Jingjing Zhang, Karin Nipsch, Danielle Meyrick, Nat Lenzo, Kalevi Kairemo, Timo Joensuu, Irene Virgolini, Cigdem Soydal, Harshad R. Kulkarni and Richard Paul Baum

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:2451-2461. https://doi.org/10.18632/oncotarget.26789

Metrics: PDF 2017 views  |   Full Text 3546 views  |   ?  


Finn Edler von Eyben1,*, Aviral Singh2,*, Jingjing Zhang2, Karin Nipsch2, Danielle Meyrick3, Nat Lenzo3,4, Kalevi Kairemo5, Timo Joensuu5, Irene Virgolini6, Cigdem Soydal7, Harshad R. Kulkarni2,# and Richard Paul Baum2,#

1Center of Tobacco Control Research, Odense, Denmark

2Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany

3GenesisCare Oncology, Theranostics, East Freemantle, Australia

4School of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia

5Docrates Cancer Center, Helsinki, Finland

6Department of Nuclear Medicine, University Hospital in Innsbruck, Innsbruck, Austria

7Department of Nuclear Medicine, University of Ankara, Faculty of Medicine, Universitesi Tip Faultesi Sikkiye, Ankara, Turkey

*These authors are first authors

#These authors are last senior authors

Correspondence to:

Finn Edler von Eyben, email: [email protected]

Keywords: metastatic prostate cancer; lutetium prostate specific membrane antigen radiolabeled radionuclide therapy; PSA response; relapse treatment; overall survival

Received: December 27, 2018     Accepted: March 04, 2019     Published: March 29, 2019


177Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with predominant lymph node metastatic prostate cancer (LNM PC). Thirty-five patients had LNM and ten patients had LNM and one or two bone metastases. Before LuPRLT, the patients had prostate specific antigen (PSA) of median 18 μg/l (interquartile range (IQR): 3.3–39). LuPRLT was given with a cumulative injected 177Lu activity of median 14.5 GBq (IQR: 12.2–20.4). Maximum percentage decline of PSA was median 92% (IQR: 70–99). Thirty-five patients with only LNM had a better overall survival (OS) than ten patients with LNM and one or two bone metastases. Thirty-three docetaxel-naïve patients had a longer PSMA PET/CT progression-free survival than twelve patients who were resistant to docetaxel. Twenty-two patients who received LuPRLT with a cumulative injected 177Lu activity ≥ 14.8 GBq had a better PSMA PET/CT progression-free survival than 23 patients who received LuPRLT with a lower cumulative injected 177Lu activity. Seventeen patients with relapse after LuPRLT who received rechallenge LuPRLT or ActPRLT had a better OS than five patients who received other forms for relapse treatment. LuPRLT gave mild and transitory adverse effects. The findings of the present study suggest that LuPRLT of patients with LNM may be effective and safe. The promising results motivate randomized phase II trials to further quantify the impact of LuPRLT as treatment of patients with LNM.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26789